인간 마이크로바이옴 시장(제5판) : 업계 동향과 세계 예측(-2035년) - 제품 유형별, 생물학적 제제 유형별, 투여 경로별, 약제 제형별, 대상 적응증별, 대상 치료 영역별 및 지역별

Human Microbiome Market: Overview

As per Roots Analysis, the human microbiome market is estimated to grow from USD 0.85 billion in the current year to USD 3.27 billion by 2035, at a CAGR of 16% during the forecast period, till 2035.

Human Microbiome Market: Growth and Trends

The human microbiome consists of a variety of microorganisms, such as bacteria, archaea, viruses, and fungi, that inhabit different regions of the human body, including the skin, gut, mouth, and other tissues. The investigation into the diversity of the human microbiome dates back to the 1680s, when Antonie van Leeuwenhoek examined his oral and fecal microbiota samples. The existing human microbiome landscape is extremely dynamic, with studies emphasizing its crucial function in immunity, metabolism, and conditions like cancer, inflammatory diseases, and even neurodegenerative disorders. The US FDA has authorized two fecal microbiota treatments to prevent recurring C. difficile infection (rCDI). Significantly, REBYOTA (created by Ferring Pharmaceutical) became the first human microbiome therapy to gain approval in November 2022, with VOWST (developed by Seres Therapeutics) also receiving approval for oral administration in April 2023. Notably, the commercial triumph of VOWST has been strengthened by Nestle Health Science's purchase of its US and worldwide rights in June 2024.

Given the continuous advancements in DNA sequencing, bioinformatics, and analytical tools that enhance our comprehension of the human microbiome in relation to health and diseases, we anticipate that this sector is poised for double-digit market growth in the near future.

Growth Drivers: Strategic Enablers of Market Expansion

Advancements in microbiome sequencing technologies, such as next-generation sequencing and metagenomics, enable deeper analysis of microbial communities, accelerating diagnostics and therapies. Further, rising investments from pharma, biotech firms, and venture capital supports expanding clinical pipelines for conditions like gastrointestinal disorders, metabolic diseases, and cancer. In addition, increasing awareness of microbiomein health, coupled with demand for personalized probiotics, preventive healthcare, and collaborations between startups and academia, further propels human microbiome market expansion.

Market Challenges: Critical Barriers Impeding Progress

While the global human microbiome market is experiencing substantial growth, there are certain restraints that can hinder the growth of this industry. High R&D and commercialization costs in the human microbiome market space including GMP facilities for live organisms and complex clinical trials, hinder scalability and adoption Stringent regulatory requirements, lack of standardized guidelines, and variability in microbial strains delay approvals and increase entry barriers across regions. Limited public understanding, ethical concerns over microbiome manipulation, and slow patient / provider adoption due to inconsistent evidence also impede progress.

Human Microbiome Market: Key Insights

The report delves into the current state of the human microbiome market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Currently, close to 215 human microbiome therapeutics developed by ~55 developers are approved / being investigated across various stages of development for treating a myriad of disorders.
• Over 50% of the human microbiome therapeutics are in clinical stages of development; notably, most of the drugs / therapy programs are focused on the development of biologics, primarily live biotherapeutics.

• Close to 140 human microbiome diagnostic tests are being developed by 75 players in this domain; notably, around 55% of the developers were established post-2015.
• Around 80% of the companies are offering human microbiome diagnostics for analysis of microfloral composition and function; 55% of players are employing sequencing / metagenomics techniques for the diagnosis.
• Majority of fecal microbiota therapy developers were established between 2000-2015; of these, more than 65% are headquartered in North America, followed by Europe (~35%).
• Fecal bacteriotherapy involves the transplantation / infusion of fecal bacteria from healthy individuals to the stomach, colon / small intestine of patients; majority (50%) of these therapies are in clinical stages.
• Close to 205 clinical trials have been registered till date to evaluate the safety and efficacy of various fecal microbiota therapies; majority of these studies have been conducted across various trial sites in Europe.
• Over the last few years, start-ups have undertaken multiple initiatives to enhance their microbiome therapeutics and diagnostics portfolio; majority of the initiatives were undertaken for the treatment of ulcerative colitis.
• The rising interest in this market is reflected from the diverse partnerships established among various stakeholders in the recent past; in fact, more than 45% of the deals were inked in the last two years.

• Since 2022, more than USD 1.2 billion has been raised in this domain; notably, grants / awards are also a very prominent funding model adopted by microbiome drug developers.
• The market impact analysis outlines the potential factors that influence the evolution of the overall market; it can be employed to determine the growth drivers, restraints, opportunities and challenges within a specific domain.
• Driven by the increasing consumer awareness gut health, the rising prevalence of chronic diseases and advancements in microbiome sequencing technologies, the market is poised for a steady growth in the future.
• Currently, amongst various routes of administration, oral route captures the highest share (55%) of the market owing to its safety, convenience and the suitability for direct therapeutic intervention within the oral cavity.

• The infectious diseases sub-segment is estimated to capture of the overall market share in the current year, owing to the effectiveness of human microbiome therapeutics in the treatment of such diseases.
• Notably, amongst various geographical regions, North America is expected to dominate the overall human microbiome market during the forecast period.
• North America is expected to capture a significant share of the overall human microbiome market in the current year owing to the rapid innovations within human microbiome sequencing technologies in the region.
• Driven by the rapid success of approved microbiome therapeutic drugs developed by prominent players in the US, the human microbiome therapeutics market is expected to grow at a steady CAGR.

Human Microbiome Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Product

• Therapeutics
• Diagnostics
• Fecal Microbiota Therapies

By Type of Biologic

• Live Biotherapeutics
• Others

By Route of Administration

• Oral Route
• Rectal Route

By Drug Formulation

• Capsule
• Suspension
• Enema
• Powder

By Target Indication

• Clostridium Difficile Infection
• Necrotizing Enterocolitis
• Irritable Bowel Syndrome
• Acute Graft Versus Host Disease
• Diabetes Mellitus
• Irritable Bowel Disease
• Colorectal Cancer

By Target Therapeutic Area

• Infectious Disorders
• Gastrointestinal Disorders
• Rare Disorders
• Metabolic Disorders
• Oncological Disorders

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• France
• Italy
• UK
• Spain
• Rest of the Europe
• Asia-Pacific
• Australia
• China
• India
• Japan
• Latin America
• Brazil
• Middle East and North Africa
• Israel
• Saudi Arabia

Human Microbiome Market: Key Segments

Market Share by Type of Product: Diagnostics Segment Hold the Largest Share

In the current year, the diagnostics segment occupies the highest market share (~45%), as per human microbiome market report, driven by increased adoption of microbiome-centered diagnostic tests for the early identification of various conditions, such as metabolic disorders and cancer-related problems. The therapeutics segment is projected to see a significant growth rate of 32% during the forecast period. This increased research and development in personalized therapies, the effectiveness of existing treatments like Fecal Microbiota Transplantation (FMT) for particular illnesses, and new drugs and therapies under development.

Human Microbiome-based Therapeutics Market Share Insights

Market Share by Type of Biologic: Live Biotherapeutics Segment Holds the Largest Market Share

Currently, the live biotherapeutics segment occupies the entire human microbiome market share (for therapeutics) owing to the increasing application of microbiome-targeted treatments for treating various conditions, such as digestive problems, metabolic disorders, and cancer-related issues. Notably, the others segment (which includes phage biologics, vaccines, and additional antibodies) is expected to experience a remarkable growth rate, with a CAGR of 64% during the forecast period.

Market Share by Route of Administration: Oral Route Segment Holds the Largest Revenue

In the current year, the oral route occupies the highest market share (55%) of human microbiome therapeutics market. It is worth noting that the therapies administered via oral route are likely to witness a substantial CAGR of 38% during the forecast period. This is associated to the safety, user-friendliness, and the ability for direct therapeutic interaction in the oral cavity to accomplish desired systemic effects.

Market Share by Drug Formulation: Suspension Segment to Grow at a Higher CAGR

Among the various segments, the capsule segment occupies the highest human microbiome therapeutics market share (55%) in 2025. This results from the strong clinical trial pipeline of microbiome-centered therapies in capsule form. It is important to highlight that the suspension segment market is expected to expand at a notably higher CAGR (38%) throughout the forecast period. This arises from its ability to maintain the viability and stability of living microbial formulations, facilitate straightforward dosage adjustments, and its long-standing application history in diverse therapeutic uses.

Market Share by Target Indication: Clostridium Difficile Infection Segment Domina

Currently, the clostridium difficile infection segment occupies the entire human microbiome therapeutics market size. This is due to the rising frequency and intensity of clostridium difficile infections, coupled with the established link between antibiotic-induced gut dysbiosis and the infection.

Further, the market for therapies targeting acute graft versus host disease is likely to grow at a relatively higher CAGR (35%), during the period 2027-2035. This is attributed to the expected endorsement of MaaT013 (Xervyteg(R)), a pioneering microbiota-centered therapy designed to meet a significant unmet need in patients suffering from GI-involved acute graft versus host disease, where existing survival rates are dangerously low and no alternative approved therapy exists.

Market Share by Target Therapeutic Area: Infectious Disorders Segment Dominates the Market

Currently, the infectious diseases segment occupies the entire human microbiome therapeutics market size (with a share of 100%) and this trend is unlikely to change in the future. This is attributed to its direct involvement in immune function and pathogen defense, along with the demonstrated effectiveness of microbiome-based treatments, such as those addressing recurrent Clostridium difficile infections. Notably, the rare disorders segment is expected to experience a comparatively higher CAGR (35%) from 2027 to 2035.

Market Share by Geographical Regions: North America with Highest Revenue

According to our projections, North America is likely to capture the majority (95%) of the human microbiome therapeutics market share in 2025, as the advanced healthcare infrastructure in North America enables developers to conduct a large number of clinical trials, in order to meet the regulatory guidelines of the approval bodies. It is worth highlighting that the market in Europe is likely to grow at a relatively higher CAGR (75%), during the period 2025-2032.

Primary Research Overview

The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Former Senior Manager, Corporate Development, Mid-Sized Company, UK
• Co-founder and Chairman, Small Company, US
• Chief Executive Officer, Small Company, US
• Senior Scientist, Large Company, US
• President, Small Company, Taiwan
• Vice President, Business Development, Small Company, US
• Chief Business Officer, Mid-sized Company, Israel
• Former Vice President, Sales and Business Development, Small Company, US
• Co-founder and Chief Executive Officer, Small Company, Belgium
• Co-founder and Chief Executive Officer, Small Company, US
• Co-founder and Chief Executive Officer, Small Company, US
• Ex-Co-founder and Vice President of Innovation, Mid-sized Company, US
• Vice President & Chief Operating Officer, Small Company, US
• Former Vice President, Operations, Mid-sized Company, US
• Former President and Chief Executive Officer, Small Company, US
• Former Chief Scientific Officer and Vice President, Research, Small Company, US
• Former Chief Strategy Officer, Small Company, France

Example Players in Human Microbiome Market

• Becton, Dickinson and Company
• Biome Diagnostics
• Ferring Pharmaceuticals
• GoodGut
• Infant Bacterial Therapeutics
• MaaT Pharma
• Microbiomik
• NutriPATH
• Seres Therapeutics
• Tiny Health
• OxThera
• Vedanta Bisociences
• Zybio

Human Microbiome Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the human microbiome market, focusing on key market segments, including [A] type of product, [B] type of biologic, [C] route of administration, [D] drug formulation, [E] target indication, [F] target therapeutic area, and [G] geographical regions.
• Human Microbiome Therapeutics - Market Landscape: A detailed overview of the current market landscape of human microbiome therapeutics, along with information on several relevant parameters, such as [A] stage of development, [B] type of molecule, [C] type of biologic, [D] target indication, [E] therapeutic area, [F] route of administration, [G] type of formulation, [H] dosage frequency, [I] type of therapy, [J] year of establishment, [K] company size, [L] location of headquarters, and [M] most active players.
• Human Microbiome Diagnostics And Screening / Profiling Tests - Market Landscape 2: A detailed overview of the current market landscape of various types of diagnostic and screening / profiling tests, along with information on several relevant parameters, such as [A] stage of development, [B] type of sample analyzed, [C] type of screening technique, [D] target indication, [E] therapeutic area, [F] purpose of test, [G] year of establishment, [H] company size, and [I] location of headquarters.
• Human Microbiome Fecal Microbiota Therapies - Market Landscape 3: A detailed overview of the current market landscape of other relevant aspects of FMT therapies, along with information on several relevant parameters, such as [A] stage of development, [B] type of sample analyzed, [C] type of screening technique, [D] target indication, [E] therapeutic area, [F] purpose of test, [G] year of establishment, [H] company size, and [I] location of headquarters.
• Company and Drug Profiles: In-depth profiles of key players engaged in the development of microbiome therapeutics, microbiome diagnostics and screening / profiling tests and fecal microbiota therapy based on [A] year of establishment, [B] location of headquarters, [C] microbiome-based drug portfolio, [D] recent developments and [E] an informed future outlook.
• Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical studies of fecal microbiota therapy, based on various relevant parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] patient gender, [D] trial phase, [E] trial status, [F] therapeutic area, [G] type of sponsor / collaborator, [H] study design, [I] most active players (in terms of number of clinical trials), and [J] geography.
• Attractiveness Competitiveness Analysis: An insightful business portfolio analysis of top indications, across various therapeutic areas under investigation, based on the 9-box AC matrix framework. It further includes a discussion on the relative market attractiveness and existing competition across the most popular disease indications.
• Partnerships and Collaborations: An in-depth analysis of the partnerships and collaborations that have been inked by human microbiome developers, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] target indication, [D] therapeutic area, [E] type of partner and [F] most active players (in terms of number of partnerships).
• Funding and Investments: A detailed analysis of the funding and investments made in this domain, based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount invested, [D] purpose of funding, [E] target indication, [F] therapeutic area, [G] geography, [H] most active players and [I] leading investors.
• Case Study 1: An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, type of product manufactured and type of formulation. In addition, the chapter highlights key consideration for selecting a CMO / CRO partner.
• Case Study 2: assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade.

Key Questions Answered in this Report

• Which are the leading companies in human microbiome market?
• Which region dominates the human microbiome market?
• What are the key trends observed in the human microbiome market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by human microbiome providers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complementary PPT Insights Pack
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Concept of Microbiota and Microbiome
  • 6.2.1. Discovery of Human Microbiome
  • 6.2.2. Functions of Human Microbiome
• 6.3. Overview of Gut Flora
  • 6.3.1. Role of Gut Flora in Human Health
  • 6.3.2. Factors Affecting Gut Flora
    • 6.3.2.1. Antibiotic Consumption
    • 6.3.2.2. Age and Pregnancy
      • 6.3.2.2.1. Mode of Childbirth
      • 6.3.2.2.2. Type of Feeding
      • 6.3.2.2.3. Antibiotic Consumption by Mother
    • 6.3.2.3. Stress-related Factors
    • 6.3.2.4. Dietary Factors
    • 6.3.2.5. Impact of Lifestyle
• 6.4. Microbiome and Associated Diseases
  • 6.4.1. Cancer
  • 6.4.2. Inflammatory Bowel Disease (IBD)
  • 6.4.3. Obesity
  • 6.4.4. Parkinson's Disease
  • 6.4.5. Type 2 Diabetes
  • 6.4.6. Other Disease Indications
• 6.5. Impact of Microbiota on Drug Pharmacokinetics
• 6.6. Impact of Microbiota on Therapeutic Outcomes
• 6.7. Microbiome Therapeutics
  • 6.7.1. Probiotics
    • 6.7.1.1. Beneficial Bacterial Strains
      • 6.7.1.1.1. Lactobacilli
      • 6.7.1.1.2. Bifidobacteria
      • 6.7.1.1.3. Others
    • 6.7.1.2. Key Therapeutic Areas
      • 6.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
      • 6.7.1.2.2. Bacterial Vaginosis
      • 6.7.1.2.3. High Blood Pressure
      • 6.7.1.2.4. Hypercholesterolemia
      • 6.7.1.2.5. Infectious Childhood Diarrhea (ICD)
      • 6.7.1.2.6. Inflammatory Bowel Disease (IBD)
      • 6.7.1.2.7. Lactose Intolerance
      • 6.7.1.2.8. Vitamin Production
      • 6.7.1.2.9. Weight Management
    • 6.7.1.3. Side Effects of Probiotics
  • 6.7.2. Prebiotics
    • 6.7.2.1. Sources of Prebiotics
    • 6.7.2.2. Types of Prebiotics
      • 6.7.2.2.1. Fructo-Oligosaccharides (FOS)
      • 6.7.2.2.2. Galacto-Oligosaccharides (GOS)
      • 6.7.2.2.3. Inulin
    • 6.7.2.3. Key Therapeutic Areas
      • 6.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
      • 6.7.2.3.2. Constipation
      • 6.7.2.3.3. Gastrointestinal Diseases
      • 6.7.2.3.4. Dysbiosis
    • 6.7.2.4. Side Effects of Prebiotics
• 6.8. The Human Microbiome Project (HMP)
  • 6.8.1. Project Approach
  • 6.8.2. Project Initiatives
  • 6.8.3. Project Achievements
• 6.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
• 6.10. Key Challenges Associated with the Development of Microbiome Therapeutics
• 6.11. Future Perspectives

7. HUMAN MICROBIOME THERAPEUTICS: MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Human Microbiome Therapeutics: Overall Market Landscape
  • 7.2.1. Analysis by Stage of Development
  • 7.2.2. Analysis by Type of Molecule
  • 7.2.3. Analysis by Stage of Development and Type of Molecule
  • 7.2.4. Analysis by Type of Biologic
  • 7.2.5. Analysis by Target Indication
  • 7.2.6. Analysis by Therapeutic Area
  • 7.2.7. Analysis by Route of Administration
  • 7.2.8. Analysis by Type of Formulation
  • 7.2.9. Analysis by Dosage Frequency
  • 7.2.10. Analysis by Type of Therapy
• 7.3. Human Microbiome Therapeutics: Developer Landscape
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters (Region)
  • 7.3.4. Analysis by Location of Headquarters (Country)
  • 7.3.5. Most Active Players: Analysis by Number of Microbiome Therapeutics

8. HUMAN MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE

• 8.1. Chapter Overview
• 8.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
• 8.3. Microbiome Diagnostics and Screening / Profiling Tests: Overall Market Landscape
  • 8.3.1. Analysis by Stage of Development
  • 8.3.2. Analysis by Type of Sample Analyzed
  • 8.3.3. Analysis by Type of Screening Technique
  • 8.3.4. Analysis by Target Indication
  • 8.3.5. Analysis by Therapeutic Area
  • 8.3.6. Analysis by Purpose of Test
• 8.4. Microbiome Diagnostic and Screening / Profiling Tests: Provider Landscape
  • 8.4.1. Analysis by Year of Establishment
  • 8.4.2. Analysis by Company Size
  • 8.4.3. Analysis by Location of Headquarters (Region)
  • 8.4.4. Analysis by Location of Headquarters (Country)
  • 8.4.5. Most Active Players: Analysis by Number of Microbiome Tests

9. HUMAN MICROBIOME FECAL MICROBOTA THERAPIES: MARKET LANDSCAPE

• 9.1. Chapter Overview
• 9.2. Introduction to Fecal Microbiota Therapies (FMT)
• 9.3. Historical Overview
• 9.4. Fecal Microbiota Therapies: Procedure and Clinical Relevance
  • 9.4.1. Donor Selection
  • 9.4.2. Administration Procedure
  • 9.4.3. Routes of Administration
  • 9.4.4. Consequences and Adverse Events
  • 9.4.5. Clinical Guidelines Associated with FMT
• 9.5. Regulatory Guidelines Related to Fecal Microbiota Therapies
• 9.6. Insurance Coverage for Fecal Microbiota Therapies
• 9.7. Fecal Microbiota Therapies: Overall Market Landscape
  • 9.7.1. Marketed / Development Pipeline
    • 9.7.1.1. Analysis by Application Area
    • 9.7.1.2. Analysis by Status of Development
    • 9.7.1.3. Analysis by Target Indication
    • 9.7.1.4. Analysis by Therapeutic Area
    • 9.7.1.5. Analysis by Route of Administration
  • 9.7.2. Fecal Microbiota Therapies: Developer Landscape
    • 9.7.2.1. Analysis by Year of Establishment
    • 9.7.2.2. Analysis by Company Size
    • 9.7.2.3. Analysis by Location of Headquarters (Region)
    • 9.7.2.4. Analysis by Location of Headquarters (Country)

10. HUMAN MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES

• 10.1. Chapter Overview
• 10.2. Ferring Pharmaceuticals
  • 10.2.1. Company Overview
  • 10.2.2. Financial Information
  • 10.2.3. Microbiome-Based Product Portfolio
    • 10.2.3.1. REBYOTA
      • 10.2.3.1.1. Drug Overview
      • 10.2.3.1.2. Current Status of Development
      • 10.2.3.1.3. Clinical Studies
  • 10.2.4. Recent Developments and Future Outlook
• 10.3. Infant Bacterial Therapeutics
• 10.4. MaaT Pharma
• 10.5. Mikrobiomik
• 10.6. Seres Therapeutics
• 10.7. OxThera
• 10.8. Vedanta Biosciences
• 10.9. Zhiyi Biotech

11. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES

• 11.1. Chapter Overview
• 11.2. Becton, Dickinson and Company
  • 11.2.1. Company Overview
  • 11.2.2. Financial Information
  • 11.2.3. Microbiome Diagnostic Test Portfolio
  • 11.2.4. Recent Developments and Future Outlook
• 11.3. Biome Diagnostics
• 11.4. GoodGut
• 11.5. NutriPATH
• 11.6. Tiny Health

12. CLINICAL TRIAL ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Fecal Microbiota Therapies: Clinical Trial Analysis
  • 12.3.1. Analysis by Trial Registration Year
  • 12.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
  • 12.3.3. Analysis by Trial Status
  • 12.3.4. Analysis of Enrolled Patient Population by Trial Status
  • 12.3.5. Analysis by Trial Registration Year and Trial Status
  • 12.3.6. Analysis by Trial Phase
  • 12.3.7. Analysis of Enrolled Patient Population by Trial Phase
  • 12.3.8. Analysis by Type of Sponsor / Collaborator
  • 12.3.9. Analysis by Study Design
  • 12.3.10. Analysis by Gender
  • 12.3.11. Leading Industry Players: Analysis by Number of Registered Trials
  • 12.3.12. Leading Non-industry Players: Analysis by Number of Registered Trials
  • 12.3.13. Analysis by Trial Status, Trial Phase and Geography
  • 12.3.14. Analysis by Geography
  • 12.3.15. Analysis by Trial Status and Geography
  • 12.3.16. Analysis of Enrolled Patient Population by Trial Status and Geography

13. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX

• 13.1. Chapter Overview
• 13.2. AC Matrix: An Overview
  • 13.2.1. Strong Business Units
  • 13.2.2. Average Business Units
  • 13.2.3. Weak Business Units
• 13.3. AC Matrix: Analytical Methodology
• 13.4. AC Matrix: Plotting the Information
• 13.5. AC Matrix: Analyzing the Data
  • 13.5.1. Strong Business Units
  • 13.5.2. Average Business Units
  • 13.5.3. Weak Business Units
• 13.6. Concluding Remarks

14. START-UP HEALTH INDEXING

• 14.1. Chapter Overview
• 14.2. Scope and Methodology
• 14.3. Benchmarking of Start-ups
  • 14.3.1. Analysis by Portfolio Strength
  • 14.3.2. Analysis by Pipeline Maturity
  • 14.3.3. Analysis by Indication Diversity
  • 14.3.4. Analysis by Funding Amount
  • 14.3.5. Analysis by Partnership Activity
  • 14.3.6. Start-up Health Indexing: Roots Analysis Perspective
  • 14.3.7. Start-up Health Indexing: Leading Companies

15. CASE STUDY: KEY THERAPEUTIC AREAS

• 15.1. Chapter Overview
• 15.2. Metabolic Disorders
  • 15.2.1. Diabetes
    • 15.2.1.1. Disease Description
    • 15.2.1.2. Associated Health Risks / Complications
    • 15.2.1.3. Epidemiology
    • 15.2.1.4. Disease Diagnosis
    • 15.2.1.5. Current Treatment Options
      • 15.2.1.5.1. Insulin Therapies
      • 15.2.1.5.2. Non-Insulin Therapies
    • 15.2.1.6. Side Effects of Current Treatment Options
    • 15.2.1.7. Microbiome Therapeutics for Diabetes
  • 15.2.2. Lactose Intolerance
    • 15.2.2.1. Disease Description
    • 15.2.2.2. Epidemiology
    • 15.2.2.3. Current Treatment Options
    • 15.2.2.4. Microbiome Therapeutics for Lactose Intolerance
  • 15.2.3. Nonalcoholic Steatohepatitis (NASH)
    • 15.2.3.1. Disease Description
    • 15.2.3.2. Epidemiology
    • 15.2.3.3. Current Treatment Options
    • 15.2.3.4. Microbiome Therapeutics for NASH
  • 15.2.4. Primary Hyperoxaluria
    • 15.2.4.1. Disease Description
    • 15.2.4.2. Epidemiology
    • 15.2.4.3. Current Treatment Options
    • 15.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria
  • 15.2.5. Obesity
    • 15.2.5.1. Disease Description
    • 15.2.5.2. Epidemiology
    • 15.2.5.3. Current Treatment Options
    • 15.2.5.4. Side Effects of Current Treatment Options
    • 15.2.5.5. Microbiome Therapeutics for Obesity
• 15.3. Digestive and Gastrointestinal Disorders
  • 15.3.1. Crohn's Disease
    • 15.3.1.1. Disease Description
    • 15.3.1.2. Epidemiology
    • 15.3.1.3. Current Treatment Options
    • 15.3.1.4. Side Effects of Current Treatment Options
    • 15.3.1.5. Microbiome Therapeutics for Crohn's Disease
  • 15.3.2. Irritable Bowel Syndrome (IBS)
    • 15.3.2.1. Disease Description
    • 15.3.2.2. Epidemiology
    • 15.3.2.3. Current Treatment Options
    • 15.3.2.4. Microbiome Therapeutics for IBS
  • 15.3.3. Ulcerative Colitis
    • 15.3.3.1. Disease Description
    • 15.3.3.2. Epidemiology
    • 15.3.3.3. Current Treatment Options
    • 15.3.3.4. Side Effects of Current Treatment Options
    • 15.3.3.5. Microbiome Therapeutics for Ulcerative Colitis
• 15.4. Oncological Indications
  • 15.4.1. Colorectal Cancer
    • 15.4.1.1. Disease Description
    • 15.4.1.2. Epidemiology
    • 15.4.1.3. Current Treatment Options
    • 15.4.1.4. Side Effects of Current Treatments
    • 15.4.1.5. Microbiome Therapeutics for Colorectal Cancer
  • 15.4.2. Lung Cancer
    • 15.4.2.1. Disease Description
    • 15.4.2.2. Epidemiology
    • 15.4.2.3. Current Treatment Options
    • 15.4.2.4. Side Effects of Current Treatment Options
    • 15.4.2.5. Microbiome Therapeutics for Lung Cancer
• 15.5. Dermatological Disorders
  • 15.5.1. Acne Vulgaris
    • 15.5.1.1. Disease Description
    • 15.5.1.2. Epidemiology
    • 15.5.1.3. Current Treatment Options
    • 15.5.1.4. Side Effects of Current Treatment Options
    • 15.5.1.5. Microbiome Therapeutics for Acne Vulgaris
• 15.6. Infectious Diseases
  • 15.6.1. Clostridium Difficile Infections (CDIs)
    • 15.6.1.1. Disease Description
    • 15.6.1.2. Epidemiology
    • 15.6.1.3. Disease Diagnosis
    • 15.6.1.4. Current Treatment Options
    • 15.6.1.5. Side Effects of Current Treatment Options
    • 15.6.1.6. Microbiome Therapeutics for CDI
  • 15.6.2. Bacterial Vaginosis
    • 15.6.2.1. Disease Description
    • 15.6.2.2. Epidemiology
    • 15.6.2.3. Current Treatment Options
    • 15.6.2.4. Side Effects of Current Treatment Options
    • 15.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

16. PARTNERSHIPS AND COLLABORATIONS

• 16.1. Chapter Overview
• 16.2. Partnership Models
• 16.3. Human Microbiome: List of Partnerships and Collaborations
• 16.4. Analysis by Year of Partnership
• 16.5. Analysis by Type of Partnership
• 16.6. Analysis by Year and Type of Partnership
• 16.7. Analysis by Target Indication
• 16.8. Analysis by Therapeutic Area
• 16.9. Analysis by Type of Partnership and Therapeutic Area
• 16.10. Analysis by Type of Partner
• 16.11. Most Active Players: Analysis by Number of Partnerships
• 16.12. Analysis by Geography
  • 16.12.1. Local and International Deals
  • 16.12.2. Intracontinental and Intercontinental Deals

17. FUNDING AND INVESTMENTS

• 17.1. Chapter Overview
• 17.2. Funding Models
• 17.3. Human Microbiome: List of Funding and Investments
  • 17.3.1. Analysis of Funding Instances by Year of Funding
  • 17.3.2. Analysis of Amount Invested by Year of Funding
  • 17.3.3. Analysis by Type of Funding
  • 17.3.4. Analysis by Year and Type of Funding
  • 17.3.5. Analysis by Amount Invested and Type of Funding
  • 17.3.6. Analysis by Purpose of Funding
  • 17.3.7. Analysis by Target Indication
  • 17.3.8. Analysis by Therapeutic Area
  • 17.3.9. Analysis by Geography
  • 17.3.10. Most Active Players: Analysis by Number of Instances
  • 17.3.11. Most Active Players: Analysis by Amount Invested
  • 17.3.12. Leading Investors: Analysis by Number of Instances
  • 17.3.13. Funding and Investment Summary

18. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS

• 18.1. Chapter Overview
• 18.2. Manufacturing Microbiome Therapeutics
  • 18.2.1. Key Steps Involved
  • 18.2.2. Associated Challenges
  • 18.2.3. Growing Demand for Contract Manufacturing Services
  • 18.2.4. Contract Manufacturing Organizations (CMOs)
    • 18.2.4.1. Introduction to Contract Manufacturing
  • 18.2.5. Microbiome Therapeutics: List of Contract Manufacturing Providers
    • 18.2.5.1. Analysis by Year of Establishment
    • 18.2.5.2. Analysis by Company Size
    • 18.2.5.3. Analysis by Location of Headquarters
    • 18.2.5.4. Analysis by Scale of Operation
    • 18.2.5.5. Analysis by Type of Product Manufactured
    • 18.2.5.6. Analysis by Type of Formulation
    • 18.2.5.7. Analysis by Scale of Operation and Type of Formulation
• 18.3. Key Considerations for Selecting a CMO / CRO Partner

19. CASE STUDY: BIG DATA AND MICROBIOME THERAPEUTICS

• 19.1. Chapter Overview
• 19.2. Introduction to Big Data
• 19.3. Internet of Things (IoT)
• 19.4. Growing Interest in Big Data: Google Trends Analysis
• 19.5. Key Application Areas
• 19.6. Big Data in Microbiome Research
  • 19.6.1. Microbiome Data and Personalized Medicine
  • 19.6.2. Microbiome-related Data Management Challenges
  • 19.6.3. National Microbiome Data Center
• 19.7. Big Data Services for Microbiome Research: List of Companies
• 19.8. Big Data Services for Microbiome Research: Profiles of Key Players
  • 19.8.1. Human Longevity
    • 19.8.1.1. Company Overview
    • 19.8.1.2. Technology and Service Portfolio
    • 19.8.1.3. Recent Developments and Future Outlook
  • 19.8.2. Resilient Biotics
    • 19.8.2.1. Company Overview
    • 19.8.2.2. Technology and Service Portfolio
    • 19.8.2.3. Recent Developments and Future Outlook
  • 19.8.3. Resphera Biosciences
    • 19.8.3.1. Company Overview
    • 19.8.3.2. Technology and Service Portfolio
    • 19.8.3.3. Recent Developments and Future Outlook

20. HUMAN MICROBIOME THERAPEUTICS MARKET

• 20.1. Chapter Overview
• 20.2. Assumptions and Methodology
• 20.3. Global Human Microbiome Therapeutics Market: Forecasted Estimates (till 2035)
• 20.4. Human Microbiome Market: Distribution by Type of Product
  • 20.4.1. Therapeutics: Forecasted Estimates (till 2035)
  • 20.4.2. Diagnostics: Forecasted Estimates (till 2035)
  • 20.4.3. Fecal Microbiota Therapies: Forecasted Estimates (till 2035)
  • 20.4.4. Scenario Analysis
    • 20.4.4.1. Conservative Scenario
    • 20.4.4.2. Optimistic Scenario
• 20.5. Key Market Segmentations

21. HUMAN MICROBIOME THERAPEUTICS MARKET, BY TYPE OF BIOLOGIC

• 21.1. Chapter Overview
• 21.2. Assumptions and Methodology
• 21.3. Distribution by Type of Biologic
  • 21.3.1. Live Biotherapeutics: Forecasted Estimates (till 2035)
  • 21.3.2. Others: Forecasted Estimates (till 2035)
• 21.4. Data Triangulation and Validation

22. HUMAN MICROBIOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Distribution by Route of Administration
  • 22.3.1. Oral Route: Forecasted Estimates (till 2035)
  • 22.3.2. Rectal Route: Forecasted Estimates (till 2035)
• 22.4. Data Triangulation and Validation

23. HUMAN MICROBIOME THERAPEUTICS MARKET, BY DRUG FORMULATION

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Distribution by Drug Formulation
  • 23.3.1. Capsules: Forecasted Estimates (till 2035)
  • 23.3.2. Suspensions: Forecasted Estimates (till 2035)
  • 23.3.3. Enemas: Forecasted Estimates (till 2035)
  • 23.3.4. Powders: Forecasted Estimates (till 2035)
• 23.4. Data Triangulation and Validation

24. HUMAN MICROBIOME THERAPEUTICS MARKET, BY TARGET INDICATION

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Distribution by Target Indication
  • 24.3.1. Clostridium Difficile Infection
  • 24.3.2. Necrotizing Enterocolitis
  • 24.3.3. Irritable Bowel Syndrome
  • 24.3.4. Acute Graft Versus Host Disease
• 24.4. Data Triangulation and Validation

25. HUMAN MICROBIOME THERAPEUTICS MARKET, BY TARGET THERAPEUTIC AREA

• 25.1. Chapter Overview
• 25.2. Key Assumptions and Methodology
• 25.3. Distribution by Therapeutic Area
  • 25.3.1. Infectious Diseases
  • 25.3.2. Gastrointestinal Disorders
  • 25.3.3. Rare Disorders
• 25.4. Data Triangulation and Validation

26. HUMAN MICROBIOME THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS

• 26.1. Chapter Overview
• 26.2. Key Assumptions and Methodology
• 26.3. Distribution by Geographical Regions
  • 26.3.1. North America
  • 26.3.2. Europe
  • 26.3.3. Asia-Pacific
  • 26.3.4. Latin America
  • 26.3.5. Middle East and North Africa
• 26.4. Market Dynamics Assessment
  • 26.4.1. Penetration Growth (P-G) Matrix
  • 26.4.2. Market Movement Analysis
• 26.5. Data Triangulation and Validation

27. HUMAN MICROBIOME DIAGNOSTICS MARKET

• 27.1. Chapter Overview
• 27.2. Assumptions and Methodology
• 27.3. Global Human Microbiome Diagnostics Market: Forecasted Estimates (till 2035)
  • 27.3.1. Scenario Analysis
• 27.4. Key Market Segmentations

28. HUMAN MICROBIOME DIAGNOSTICS MARKET, BY TARGET INDICATION

• 28.1. Chapter Overview
• 28.2. Key Assumptions and Methodology
• 28.3. Market Distribution by Target Indication
  • 28.3.1. Diabetes Mellitus: Forecasted Estimates (till 2035)
  • 28.3.2. Irritable Bowel Syndrome: Forecasted Estimates (till 2035)
  • 28.3.3. Irritable Bowel Disease: Forecasted Estimates (till 2035)
  • 28.3.4. Colorectal Cancer: Forecasted Estimates (till 2035)
• 28.4. Data Triangulation and Validation

29. HUMAN MICROBIOME DIAGNOSTICS MARKET, BY TARGET THERAPEUTIC AREA

• 29.1. Chapter Overview
• 29.2. Key Assumptions and Methodology
• 29.3. Market Distribution by Therapeutic Area
  • 29.3.1. Gastrointestinal Disorders: Forecasted Estimates (till 2035)
  • 29.3.2. Metabolic Disorders: Forecasted Estimates (till 2035)
  • 29.3.3. Oncological Disorders: Forecasted Estimates (till 2035)
• 29.4. Data Triangulation and Validation

30. HUMAN MICROBIOME DIAGNOSTICS MARKET, BY GEOGRAPHICAL REGIONS

• 30.1. Chapter Overview
• 30.2. Key Assumptions and Methodology
• 30.3. Market Distribution by Geographical Regions
  • 30.3.1. North America: Forecasted Estimates (till 2035)
  • 30.3.2. Europe: Forecasted Estimates (till 2035)
  • 30.3.3. Asia-Pacific: Forecasted Estimates (till 2035)
  • 30.3.4. Latin America: Forecasted Estimates (till 2035)
  • 30.3.5. Middle East and North Africa: Forecasted Estimates (till 2035)
• 30.4. Data Triangulation and Validation
• 30.5. Market Dynamics Assessment
  • 30.5.1. Penetration Growth (P-G) Matrix
  • 30.5.2. Market Movement Analysis
• 30.6. Data Triangulation and Validation

31. HUMAN MICROBIOME FECAL MICROBIOTA THERAPIES MARKET

• 31.1. Chapter Overview
• 31.2. Assumptions and Methodology
• 31.3. Global Market: Forecasted Estimates (till 2035)
  • 31.3.1. Scenario Analysis
    • 31.3.1.1. Conservative Scenario
    • 31.3.1.2. Optimistic Scenario
• 31.4. Key Market Segmentations

32. HUMAN MICROBIOME FECAL MICROBIOTA THERAPIES MARKET, BY GEOGRAPHIC REGIONS

• 32.1. Chapter Overview
• 32.2. Key Assumptions and Methodology
• 32.3. Distribution by Geographic Regions
  • 32.3.1. North America
  • 32.3.2. Europe
  • 32.3.3. Asia-Pacific
  • 32.3.4. Latin America
  • 32.3.5. Middle East and North Africa
• 32.4. Data Triangulation and Validation
• 32.5. Market Dynamics Assessment
  • 32.5.1. Penetration Growth (P-G) Matrix
  • 32.5.2. Market Movement Analysis
• 32.6. Data Triangulation and Validation

33. HUMAN MICROBIOME THERAPEUTICS MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 33.1. Market Distribution by Type of Biologic
• 33.2. Market Distribution by Route of Administration
• 33.3. Market Distribution by Drug Formulation
• 33.4. Market Distribution by Target Indication
• 33.5. Market Distribution by Target Therapeutic Area

34. HUMAN MICROBIOME THERAPEUTICS MARKET OPPORTUNITY ANALYSIS: EUROPE

• 34.1. Market Distribution by Type of Biologic
• 34.2. Market Distribution by Route of Administration
• 34.3. Market Distribution by Drug Formulation
• 34.4. Market Distribution by Target Indication
• 34.5. Market Distribution by Target Therapeutic Area

35. HUMAN MICROBIOME THERAPEUTICS MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

• 35.1. Market Distribution by Type of Biologic
• 35.2. Market Distribution by Route of Administration
• 35.3. Market Distribution by Drug Formulation
• 35.4. Market Distribution by Target Indication
• 35.5. Market Distribution by Target Therapeutic Area

36. HUMAN MICROBIOME THERAPEUTICS MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

• 36.1. Market Distribution by Type of Biologic
• 36.2. Market Distribution by Route of Administration
• 36.3. Market Distribution by Drug Formulation
• 36.4. Market Distribution by Target Indication
• 36.5. Market Distribution by Target Therapeutic Area

37. HUMAN MICROBIOME THERAPEUTICS MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

• 37.1. Market Distribution by Type of Biologic
• 37.2. Market Distribution by Route of Administration
• 37.3. Market Distribution by Drug Formulation
• 37.4. Market Distribution by Target Indication
• 37.5. Market Distribution by Target Therapeutic Area

38. HUMAN MICROBIOME DIAGNOSTICS MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 38.1. Distribution by Target Indication
• 38.2. Distribution by Target Therapeutic Area

39. HUMAN MICROBIOME DIAGNOSTICS MARKET OPPORTUNITY ANALYSIS: EUROPE

• 39.1. Distribution by Target Indication
• 39.2. Distribution by Target Therapeutic Area

40. HUMAN MICROBIOME DIAGNOSTICS MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

• 40.1. Distribution by Target Indication
• 40.2. Distribution by Target Therapeutic Area

41. HUMAN MICROBIOME DIAGNOSTICS MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

• 41.1. Distribution by Target Indication
• 41.2. Distribution by Target Therapeutic Area

42. HUMAN MICROBIOME DIAGNOSTICS MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

• 42.1. Distribution by Target Indication
• 42.2. Distribution by Target Therapeutic Area

43. CONCLUDING INSIGHTS

44. EXECUTIVE INSIGHTS

• 44.1. Chapter Overview
• 44.2. Company A (Mid-sized Company, UK)
  • 44.2.1. Company Snapshot
  • 44.2.2. Interview Transcript: Former Senior Manager, Corporate Development
• 44.3. Company B (Small Company, US)
  • 44.3.1. Company Snapshot
  • 44.3.2. Interview Transcript: Co-founder and Chairman
• 44.4. Company C (Small Company, US)
  • 44.4.1. Company Snapshot
  • 44.4.2. Interview Transcript: Chief Executive Officer
• 44.5. Company D (Large Company, US)
  • 44.5.1. Company Snapshot
  • 44.5.2. Interview Transcript: Senior Scientist
• 44.6. Company E (Small Company, Taiwan)
  • 44.6.1. Company Snapshot
  • 44.6.2. Interview Transcript: President
• 44.7. Company F (Small Company, US)
  • 44.7.1. Company Snapshot
  • 44.7.2. Interview Transcript: Vice President, Business Development
• 44.8. Company G (Mid-sized Company, Israel)
  • 44.8.1. Company Snapshot
  • 44.8.2. Interview Transcript: Chief Business Officer
• 44.9. Company H (Small Company, US)
  • 44.9.1. Company Snapshot
  • 44.9.2. Interview Transcript: Former Vice President, Sales and Business Development
• 44.10. Company I (Small Company, Belgium)
  • 44.10.1. Company Snapshot
  • 44.10.2. Interview Transcript: Co-founder and Chief Executive Officer
• 44.11. Company J (Small Company, US)
  • 44.11.1. Company Snapshot
  • 44.11.2. Interview Transcript: Co-founder and Chief Executive Officer
• 44.12. Company K (Small Company, US)
  • 44.12.1. Company Snapshot
  • 44.12.2. Interview Transcript: Co-founder and Chief Executive Officer
• 44.13. Company L (Mid-sized Company, US)
  • 44.13.1. Company Snapshot
  • 44.13.2. Interview Transcript: Ex-Co-founder and Vice President of Innovation
• 44.14. Company M (Small Company, US)
  • 44.14.1. Company Snapshot
  • 44.14.2. Interview Transcript: Vice President & Chief Operating Officer
• 44.15. Company N (Mid-sized Company, US)
  • 44.15.1. Company Snapshot
  • 44.15.2. Interview Transcript: Former Vice President, Operations
• 44.16. Company O (Small Company, US)
  • 44.16.1. Company Snapshot
  • 44.16.2. Interview Transcript: Former President and Chief Executive Officer
• 44.17. Company P (Small Company, US)
  • 44.17.1. Company Snapshot
  • 44.17.2. Interview Transcript: Former Chief Scientific Officer and Vice President, Research
• 44.18. Company Q (Small Company, France)
  • 44.18.1. Company Snapshot
  • 44.18.2. Interview Transcript: Former Chief Strategy Officer

45. APPENDIX I: TABULATED DATA

46. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS